Search results

The market expects Charles River Laboratories (CRL) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known

Charles River Laboratories International, Inc. CRL is scheduled to report second-quarter 2026 results on Aug. 5, before market open.

In the last reported quarter, the company’s adjusted earnings per

Charles River Laboratories (CRL) came out with quarterly earnings of $3.02 per share, beating the Zacks Consensus Estimate of $2.72 per share. This compares to earnings of $3.12 per share a year

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Charles River Laboratories (CRL) is a stock that can certainly grab the attention

For the quarter ended June 2026, Charles River Laboratories (CRL) reported revenue of $1 billion, down 2.7% over the same period last year. EPS came in at $3.02, compared to $3.12 in the year-ago

Have you looked into how Charles River Laboratories (CRL) performed internationally during the quarter ending June 2026? Considering the widespread global presence of this medical research equipment

Charles River Laboratories International, Inc. CRL reported second-quarter 2026 company-defined non-GAAP earnings of $3.02 per share, down 3.2% year over year. The reported earnings topped the Zacks

Charles Schwab SCHW, one of the leading brokerage firms in the United States, has seen its stock rise almost 6% in a month. The company’s shares even hit an all-time high of $109.05 during

Charles River Associates CRAI reported second-quarter 2026 adjusted earnings of $2.16 per share, up 14.9% year over year, beating the Zacks Consensus Estimate of $2.12 by 1.9%. Revenues rose 12.8%